All Stories

Agomab’s ALK5 inhibitor hits target in phase 2 Crohn’s disease trial

Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of fibrostenosing Crohn’s disease.

Mar 10, 2025 - 13:58
 0
Agomab’s ALK5 inhibitor hits target in phase 2 Crohn’s disease trial
Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of fibrostenosing Crohn’s disease.
Read More

Tags:

Previous Article

Rwanda takes first steps to decarbonise public transport

Next Article

Mango sales and profits jump as it invests heavily in global ops

Related Posts

Praxis flouts phase 3 futility finding, forging ahead with tremor trial despite interim setback

Praxis flouts phase 3 futility finding, forging ahead w...

Feb 28, 2025  0

Trump administration layoffs hit FDA’s device center

Trump administration layoffs hit FDA’s device center

Feb 18, 2025  0

How To Check Transmission Fluid: A Complete Guide

Mar 8, 2025  0